Longevity · Mitochondrial-derived peptide (MDP) · Compounded 503A
Humanin: the mitochondrial-derived longevity peptide.
Humanin is a 24-amino-acid peptide encoded within mitochondrial DNA — one of a small family of mitochondrial-derived peptides (MDPs) discovered in the 2000s. Higher endogenous humanin levels are associated with longevity, including in the offspring of centenarians, and the peptide demonstrates broad cytoprotective activity in preclinical models.
What Humanin is
Humanin is a 24-amino-acid peptide encoded within the mitochondrial 16S rRNA gene — one of the first mitochondrial-derived peptides (MDPs) identified, alongside MOTS-c and the SHLP family.
It was discovered in 2001 by a Japanese group searching for protective factors against Alzheimer's-related amyloid toxicity. Subsequent work established its broad cytoprotective activity across neurons, cardiomyocytes, beta cells, and other tissues.
Higher endogenous humanin levels are observed in healthy long-lived individuals and the offspring of centenarians — a striking association that has driven sustained interest in therapeutic humanin.
How it works
Humanin binds a cell-surface receptor complex (CNTFR/WSX-1/gp130) on multiple tissues, activating STAT3 and ERK signaling cascades that drive cytoprotective gene programs.
Intracellularly, humanin binds and inhibits Bax — a pro-apoptotic protein. This blocks the mitochondrial pathway of apoptosis in neurons, beta cells, and other tissues under stress.
Humanin also supports metabolic homeostasis through actions on the hypothalamus, liver, and beta cells — relevant for glucose regulation and insulin sensitivity in aging.
What patients use it for
Neuroprotection
Original discovery context — humanin protects neurons from amyloid-β toxicity in Alzheimer's disease models, with broader neuroprotective activity in ischemic and toxic injury.
Cellular resilience
Anti-apoptotic activity across multiple cell types supports cellular survival under stress — the foundation of its longevity-association signal.
Metabolic support
Humanin supports glucose regulation and insulin sensitivity through actions on the hypothalamus, liver, and pancreatic beta cells.
Cardioprotection
Preclinical work has demonstrated cardioprotective activity in ischemia-reperfusion injury models — relevant in the broader longevity-axis context.
Evidence summary
Hashimoto Y et al. (PNAS, 2001) — the original discovery paper identifying humanin as a peptide protective against Alzheimer's-related neuronal death.
Muzumdar RH et al. (PLOS One, 2009) demonstrated metabolic and cardiovascular effects of humanin including improved insulin sensitivity in aged animals.
Yen K et al. (Aging Cell, 2018) showed elevated humanin levels in long-lived individuals and in the offspring of centenarians — a key longevity-association paper.
Honest framing: foundational biology is strong and replicated across many labs; direct human therapeutic RCT data is limited.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Most commonly subcutaneous injection. Course-based use (8–12 weeks) is typical.
Often paired with MOTS-c and other MDPs in longevity-axis protocols — the MDPs are mechanistically complementary.
Compounded humanin from licensed 503A pharmacies is the typical U.S. dispensing pathway. Not FDA-approved.
Safety and contraindications
Human safety data is limited. Generally well-tolerated in early clinical experience.
Theoretical concerns: cytoprotection mechanisms could theoretically support tumor cell survival. Active malignancy is a contraindication.
Contraindications: pregnancy, lactation, active malignancy, known hypersensitivity. Use under physician supervision.
Who it's typically considered for
- Adults with a longevity-axis orientation and interest in MDPs (humanin, MOTS-c)
- Patients with metabolic dysfunction interested in mitochondrial-axis interventions
- Adults with cognitive aging concerns under physician supervision
- Patients comfortable with the honest evidence framing — strong biology, early human clinical
Frequently asked questions
Is humanin FDA-approved?
No. Humanin is investigational; compounded preparations are dispensed by licensed 503A pharmacies under physician prescription for off-label use.
Humanin vs MOTS-c — which?
Both are mitochondrial-derived peptides with cytoprotective and metabolic activity. They are commonly used together rather than as alternatives — mechanistically complementary.
Will humanin extend my lifespan?
No human RCT has demonstrated lifespan extension from exogenous humanin. The association in long-lived individuals is correlational. Honest framing matters here.
How quickly does humanin work?
Subjective effects are typically gradual over weeks. The cytoprotective and metabolic mechanisms build with sustained dosing rather than producing acute changes.
Can humanin help in menopause?
Mitochondrial function declines with estradiol loss, and many midlife symptoms have a mitochondrial component. Humanin's mechanism is well-aligned, though direct RCT data in menopause is not yet published.
Is humanin safe long-term?
Long-term human safety is not fully characterized. Course-based protocols with reassessment are appropriate.
Does humanin help insulin sensitivity?
Preclinical work supports a metabolic effect. Direct human RCT data on insulin sensitivity is limited.
Sources
- Hashimoto Y et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. PNAS (2001). — pubmed.ncbi.nlm.nih.gov/11371646
- Muzumdar RH et al. Humanin: a novel central regulator of peripheral insulin action. PLOS One (2009). — pubmed.ncbi.nlm.nih.gov/19568435
- Yen K et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (2020). — pubmed.ncbi.nlm.nih.gov/32534446
- Lee C et al. Humanin: a harbinger of mitochondrial-derived peptides? Trends in Endocrinology & Metabolism (2013). — pubmed.ncbi.nlm.nih.gov/23375520
Considering Humanin?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.